June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Electroretinograms Ordered for Vigabatrin Use at the Children’s Hospital Colorado
Author Affiliations & Notes
  • Ashley Laing
    Ophthalmology, University of Colorado, Denver, CO
  • Jennifer Jung
    Ophthalmology, University of Colorado, Denver, CO
  • Emily McCourt
    Ophthalmology, University of Colorado, Denver, CO
    Ophthalmology, Children's Hospital of Colorado, Aurora, CO
  • Rebecca Braverman
    Ophthalmology, University of Colorado, Denver, CO
    Ophthalmology, Children's Hospital of Colorado, Aurora, CO
  • Footnotes
    Commercial Relationships Ashley Laing, None; Jennifer Jung, None; Emily McCourt, None; Rebecca Braverman, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 5103. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ashley Laing, Jennifer Jung, Emily McCourt, Rebecca Braverman; Electroretinograms Ordered for Vigabatrin Use at the Children’s Hospital Colorado. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5103. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Vigabatrin is an anti-epileptic medication commonly used for intractable seizure disorders in children. Although this medication is often successful in treating seizures, Vigabatrin can cause visual field defects as well as changes on the electroretinogram (ERG). The traditional method of monitoring for Vigabatrin toxicity in adults includes serial visual field testing. In young children or children with developmental delay, visual field testing is not possible and thus current practice includes monitoring with ERGs every six months. The recommendations regarding monitoring while on Vigabatrin are controversial and it is unclear if the results of the ERGs change the management of these patients.

Methods: Retrospective chart review of ERGs ordered at the Children’s Hospital Colorado from 2009 to 2012.

Results: 157 ERGs were performed at the Children’s Hospital Colorado between May 1st, 2009 and January 13th, 2012. 133 ERG results were available for analysis. Thirty-seven of 157 ERGs performed were for Vigabatrin use. Thirty-five of the 37 (94.6%) ERGs performed for Vigabatrin use were abnormal. Vigabatrin was discontinued due to abnormal ERG results in one of the 35 (2.85%) patients with abnormal results.

Conclusions: Vigabatrin is a commonly used anti-epileptic medication in patients with intractable seizures, however there are known side effects of the drug including visual field defects and ERG abnormalities. It is unclear at this time if electroretinograms are the most cost-effective and efficient way to monitor for Vigabatrin toxicity.

Keywords: 509 electroretinography: clinical • 688 retina  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×